What are the treatment options for migraine prophylaxis to prevent phantosmia?

Treatment Options for Migraine Prophylaxis to Prevent Phantosmias

Standard migraine prophylactic medications should be used to prevent phantosmias (olfactory hallucinations), as these represent an uncommon but distinctive form of migraine aura that typically diminish or disappear with initiation of prophylactic therapy for headaches 1.

Understanding Phantosmias in Migraine

Phantosmias are olfactory hallucinations that occur in approximately 0.66% of migraine patients 1. These hallucinations typically:

• Last 5-60 minutes
• Occur shortly before or simultaneous with headache onset
• Present as highly specific, unpleasant odors (most commonly burning smells)
• Occur predominantly in women with migraine 1

The key clinical insight is that phantosmias respond to standard migraine prophylaxis - in the majority of patients, these olfactory hallucinations diminished or disappeared when prophylactic therapy was initiated 1.

First-Line Prophylactic Options

Based on the most recent 2025 American College of Physicians guideline 2 and international consensus 3, prioritize medications by cost and efficacy:

Beta-Blockers (Start Here)

• Propranolol: 80-160 mg daily in long-acting formulations 3
• Metoprolol: 50-100 mg twice daily or 200 mg modified-release once daily 3
• Atenolol: 25-100 mg twice daily 3
• Bisoprolol: 5-10 mg once daily 3

Contraindications: Asthma, cardiac failure, Raynaud disease, atrioventricular block, depression 3

Anticonvulsants

• Topiramate: 50-100 mg daily 3 - Start low (25 mg) and titrate slowly
  • Particularly useful if patient has comorbid obesity (causes weight loss) 3
  • Contraindications: Nephrolithiasis, pregnancy, lactation, glaucoma 3

Angiotensin II-Receptor Blocker

• Candesartan: 16-32 mg daily 3
  • Consider if ACE inhibitors/ARBs align with comorbidities (hypertension)

Second-Line Options

If first-line treatments fail after 2-3 months at therapeutic doses 2, 3:

• Amitriptyline: 10-100 mg at night 3

  • Particularly useful if comorbid depression or sleep disturbances 3
  • Contraindications: Age <6 years, heart failure, co-administration with MAOIs/SSRIs, glaucoma 3

• Flunarizine: 5-10 mg once daily 3

  • Contraindications: Parkinsonism, depression 3

• Sodium valproate: 600-1,500 mg daily 3

  • Absolutely contraindicated in women of childbearing potential 3

Third-Line Options (If Multiple Failures)

• CGRP monoclonal antibodies 3:

  • Erenumab: 70 or 140 mg subcutaneous monthly
  • Fremanezumab: 225 mg monthly or 675 mg quarterly
  • Eptinezumab: 100 or 300 mg IV quarterly
  • Note: Cost and insurance restrictions typically limit use 2

• OnabotulinumtoxinA: 155-195 units to 31-39 sites every 12 weeks 3

  • Reserved for chronic migraine (≥15 headache days/month) 3

Alternative Considerations from ACP Guidelines

If recommended treatments are not tolerated or result in inadequate response 2:

• Lisinopril (ACE inhibitor)
• Candesartan or telmisartan (ARBs)
• Fluoxetine (SSRI)

Critical Implementation Points

Dosing Strategy

Start low and go slow 2, 3. Initiate at low doses and gradually increase until desired outcomes are achieved. This minimizes adverse events and improves adherence.

Timeline for Assessment

• Oral medications: Assess efficacy after 2-3 months at therapeutic dose 2, 3
• CGRP antibodies: Assess after 3-6 months 3
• OnabotulinumtoxinA: Assess after 6-9 months 3

Critical pitfall: Patients often abandon treatment prematurely. Emphasize that improvement occurs gradually, often becoming apparent only after the first few weeks 2.

When to Switch

Switch medications if 2:

• Inadequate response after 2-3 months at therapeutic dose
• Adverse events occur (can switch earlier)
• Failure of one class does not predict failure of another class

Monitoring

Use headache diaries to 2:

• Determine treatment efficacy
• Identify analgesic overuse (which can cause medication overuse headache)
• Track migraine progression

Special Consideration for Phantosmias

The evidence specifically demonstrates that phantosmias in migraine patients respond to standard prophylactic therapy 1. One case report showed successful control with lamotrigine 4, though this is not a standard first-line agent. The key principle is that treating the underlying migraine with standard prophylaxis addresses the phantosmia symptom 1.

Cost Considerations

The 2025 ACP guideline explicitly prioritizes cost 2. Given similar net benefits across recommended treatments, prescribe less costly medications first (beta-blockers, topiramate, amitriptyline) before advancing to expensive CGRP antibodies, which should be reserved for patients who have failed multiple oral preventives.

Duration of Treatment

Consider pausing prophylaxis after 6-12 months of successful treatment 3 to determine if continued therapy is necessary. This minimizes unnecessary drug exposure while maintaining control.